PD-1 monoclonal antibody
- Generic Name
- PD-1 monoclonal antibody
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Beijing 302 Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT06364787
Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
- Conditions
- HCC
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Chen Xiaoping
- Target Recruit Count
- 300
- Registration Number
- NCT06311929
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, Wuhan, Hubei, China
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
- Conditions
- Colorectal CancerGastric CancerEsophageal Cancer
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 268
- Registration Number
- NCT06008054
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
- Conditions
- Angioimmunoblastic T-cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise Specified
- Interventions
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Ou Bai, MD/PHD
- Target Recruit Count
- 34
- Registration Number
- NCT05821192
- Locations
- 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 36
- Registration Number
- NCT05039580
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Ablation Combined With PD-1 in HCC: Phase II Study
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Procedure: Radiofequencey or microwave ablation
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT04652440
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT04478461
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
PD-1 Monoclonal Antibody in Pre-treated Lymphoepithelioma-like Carcinoma
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2020-06-12
- Target Recruit Count
- 12
- Registration Number
- NCT04430166
- Locations
- 🇨🇳
Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Peking University
- Target Recruit Count
- 134
- Registration Number
- NCT03874897
- Locations
- 🇨🇳
The First Affiliated Hospital , Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Department of GI Oncology, Peking University Cancer Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.